MedTrace Logo

Study Evaluating Vaccine in Adults With HIV

NCT00195312 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2007-12-05

No results posted yet for this study

Summary

The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV.

A second purpose for this study is to understand how your immune system responds to the study vaccine with the adjuvants. Understanding these differences could be useful in several ways. First, it might help identify people whose disease is likely to respond to the study vaccine with the study adjuvants. Second, the information might be useful in developing other treatments for people whose disease does not respond to the study vaccine with the adjuvants.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

HIV-1 gag DNA (formulated with bupivacaine)

BIOLOGICAL

IL-15 DNA (formulated with bupivacaine)

BIOLOGICAL

IL-12 DNA (formulated with bupivacaine)

BIOLOGICAL

Sodium chloride injection USP (0.9%)

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Completion
2007-08-31

Countries

  • United States
  • Germany
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00195312 on ClinicalTrials.gov